Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer

Hisatsugu Goto(Tokushima University), Yasuhiko Nishioka(Tokushima University), Tomoyuki Urata(Kochi Medical School Hospital), Masaki Hanibuchi(Tokushima University), Takanori Kanematsu(Matsuyama Red Cross Hospital), Hisanori Machida(National Hospital Organization Kochi National Hospital), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Yoshio Okano(Toneyama National Hospital), Nobuo Hatakeyama(National Hospital Organization Kochi National Hospital), Fumitaka Ogushi(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Takashi Haku(Tokushima Prefectural Central Hospital)
Respiratory Investigation
October 23, 2017
10.1016/j.resinv.2017.09.003
Cited by 13

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124